ArticleMolecular diversity2026
Exploring the molecular mechanism of benzo[a]pyrene affecting prostate cancer based on network toxicology and external validation.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Benzo[a]pyrene (BaP) is a polycyclic fragrant hydrocarbon contaminant commonly establish throughout the surroundings. The International Agency for Research on Cancer has classified it as a Group 1 carcinogen; however, its exact contribution to the onset of prostate cancer (PCa) is still not well defined. This study systematically explores the mechanism underlying the association between BaP exposure and prostate cancer using approaches including network toxicology, machine learning, transcriptomic validation, immune infiltration assessment, single-cell analysis, molecular docking and external validation. The results showed that BaP and prostate cancer shared 975 overlapping targets, which were predominantly enriched in signaling pathways such as PI3K-Akt. Four core genes were screened out through differential analysis and machine learning, namely CAV1, TWIST1, PRKCA, and GDF15. Transcriptome verification showed that TWIST1 and GDF15 were up-regulated, CAV1 and PRKCA were down-regulated, and the AUC of the four-gene combined diagnosis reached 0.990. Core genes are associated with cellular growth and immune cell recruitment, and single-cell sequencing verified their specific cellular distribution and immunological shifts. Molecular docking showed that BaP binds well to the core target. External validation confirmed that BaP may promotes the progression of PCa, with upregulated expression of GDF15 and downregulated expression of PRKCA in PCa. In conclusion, BaP may promote the development of PCa by regulating pathways such as CAV1, TWIST1, GDF15 and PRKCA.
Indexed as
Identifiers
42776424What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.